Equities Analysts Offer Predictions for TNDM FY2029 Earnings

Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) - Leerink Partnrs issued their FY2029 EPS estimates for shares of Tandem Diabetes Care in a report released on Thursday, February 27th. Leerink Partnrs analyst M. Kratky forecasts that the medical device company will post earnings per share of $0.73 for the year. The consensus estimate for Tandem Diabetes Care's current full-year earnings is ($1.68) per share.

Other equities analysts have also recently issued research reports about the stock. Morgan Stanley raised shares of Tandem Diabetes Care from an "equal weight" rating to an "overweight" rating and set a $45.00 price target for the company in a research report on Monday, December 2nd. Sanford C. Bernstein cut shares of Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and decreased their price target for the company from $35.00 to $25.00 in a research report on Friday. Citigroup decreased their price target on shares of Tandem Diabetes Care from $57.00 to $50.00 and set a "buy" rating for the company in a research report on Wednesday, December 11th. Canaccord Genuity Group restated a "buy" rating and issued a $63.00 price objective on shares of Tandem Diabetes Care in a report on Wednesday, February 26th. Finally, Royal Bank of Canada reduced their price objective on shares of Tandem Diabetes Care from $65.00 to $55.00 and set an "outperform" rating on the stock in a report on Thursday. Six equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $48.44.

Tandem Diabetes Care Stock Down 2.2 %

TNDM stock traded down $0.48 during midday trading on Friday, hitting $21.66. The company's stock had a trading volume of 1,299,490 shares, compared to its average volume of 1,369,065. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29. Tandem Diabetes Care has a 52-week low of $20.36 and a 52-week high of $53.69. The firm has a market capitalization of $1.44 billion, a P/E ratio of -11.22 and a beta of 1.32. The firm has a 50-day simple moving average of $34.95 and a 200-day simple moving average of $36.32.

Institutional Investors Weigh In On Tandem Diabetes Care

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in Tandem Diabetes Care by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 7,440,005 shares of the medical device company's stock worth $267,989,000 after acquiring an additional 77,451 shares in the last quarter. ArrowMark Colorado Holdings LLC grew its position in Tandem Diabetes Care by 14.1% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 2,723,715 shares of the medical device company's stock worth $98,108,000 after purchasing an additional 337,026 shares during the last quarter. State Street Corp grew its position in Tandem Diabetes Care by 3.2% during the 3rd quarter. State Street Corp now owns 2,655,736 shares of the medical device company's stock worth $112,630,000 after purchasing an additional 83,172 shares during the last quarter. GW&K Investment Management LLC grew its position in Tandem Diabetes Care by 18.0% during the 4th quarter. GW&K Investment Management LLC now owns 2,123,488 shares of the medical device company's stock worth $76,488,000 after purchasing an additional 323,674 shares during the last quarter. Finally, Bellevue Group AG grew its position in Tandem Diabetes Care by 19.9% during the 3rd quarter. Bellevue Group AG now owns 1,850,891 shares of the medical device company's stock worth $78,496,000 after purchasing an additional 307,624 shares during the last quarter.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.